ClinicalTrials.gg
CompletedNCT00773175PEDs-IIUpdated Nov 7, 2018Results posted

Subcutaneous Rehydration Compared to Intravenous Rehydration

A Phase 4 interventional study of recombinant human hyaluronidase in Dehydration, sponsored by Halozyme Therapeutics. Completed at 25 sites in United States. Open to participants aged 30 Days to 10 Years. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by Halozyme Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
30 Days to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.

Enrollment
7th of 74
148 · median 30
Started
2008
with 1 other
Phase 4
6 of 87
none open now
Registered
7th of 87
by date

Among the 87 studies in Dehydration with a site in United States, this one is the 7th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 7th registered.

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

Browse Dehydration studies →

Open to participants now

7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 30 Days to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Dehydration with a site in United States, or all of them as a file.
02

Study summary

Randomized (1:1 ratio) study of subcutaneous (SC) versus intravenous (IV) fluid rehydration in mildly to moderately dehydrated pediatric patients.

Read the detailed description

This is a prospective, randomized (1:1 ratio), open-label, parallel group, multicenter, multi-national, study of SC versus IV fluid rehydration in mildly to moderately dehydrated pediatric patients treated in the Emergency Department (ED), inpatient pediatric unit, and/or outpatient urgent care facility. It is expected that up to 186 patients, in order to achieve 148 evaluable patients, will be randomized in a 1:1 ratio to receive isotonic fluid rehydration by either SC administration with hylenex (150 Units) or IV without hylenex.

03

Conditions studied

  • Dehydration

Browse trials for

Keywords

  • pediatric
  • hylenex
  • subcutaneous infusion
  • hyaluronidase
  • rHuPH20
  • recombinant human hyaluronidase
04

Who can participate

Ages eligible
30 Days to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of either gender from one month to ≤10 years of age.
  • Patients with mild or moderate dehydration
  • Healthy child except for the underlying etiology for dehydration
  • Pre-dehydration body weight ≥ 5th percentile for age
  • Parents or legal guardian(s) available to provide .

Exclusion criteria

Exclusion Criteria:

  • Severe dehydration
  • Shock or life-threatening situation ( \< 10 days).
  • Requirement for IV access for any indication other than for treatment of dehydration.
  • Indwelling IV catheter, except for one intended only for collection of clinical laboratory specimens.
  • Any condition precluding SC infusion or infusion site evaluation
  • Any reason (prior to study enrollment) for a hospital admission or an extended stay in the ED for other than dehydration.
  • Known to hyaluronidase or hylenex.
  • Known hyponatremia (\< 130 milliequivalents per liter [mEq/L]) or hypernatremia (> 155 mEq/L).
  • Known hypokalemia (\< 3.0 mEq/L).
  • Any medical condition likely to interfere with the patient's ability to fully complete all protocol-specified interventions, the ability to undergo all protocol-specified assessments, or likely to prolong the patient's need for medical attention beyond that required for treatment of dehydration.
  • Participation in an drug or device study within 30 days prior to enrollment in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Active comparator
    Subcutaneous

    Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)

    Drug: recombinant human hyaluronidase

  • Active comparator
    Intravenous

    Isotonic fluid rehydration by IV

    Drug: recombinant human hyaluronidase

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Randomized Participants

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  2. Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  3. Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Rescued Participants

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

Secondary outcomes

  1. Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  2. Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants Achieving > 200 mL

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the Food and Drug Administration (FDA) removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  3. Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants Achieving > 200 mL

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  4. Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Rescued Participants Achieving > 200 mL

    It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  5. Mean Flow Rate, Delivered Per Unit Time, for All Randomized Participants

    The mean flow rate was averaged over any 60-minute period of time.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  6. Mean Flow Rate, Delivered Per Unit Time, for All Non-rescued Participants

    The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  7. Mean Flow Rate, Delivered Per Unit Time, for All Rescued Participants

    The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  8. Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Randomized Participants

    The mean flow rate was averaged over any 60-minute period of time.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  9. Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Non-rescued Participants

    The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  10. Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Rescued Participants

    The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  11. Number of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration

    The maximum flow rate was averaged over any 60-minute period of time.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  12. Number of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration

    The number of participants administered at least 20 mL total volume was assessed.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  13. Number of Participants With the Indicated Type of Adverse Events

    Adverse events (AEs) are defined as any untoward medical occurrence in a participant administered a product, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events (TEAEs) are defined as those events that occurred on or after the first injection device insertion attempt.

    Time frame: up to 7 days after hospital discharge

  14. Number of Participants With Normal Physical Examination Findings at Baseline That Shifted to Abnormal at the End of Fluid Administration

    Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion. Not Rel Dehy = Abnormal, Not Related to Dehydration; Rel Dehy = Abnormal, Related to Dehydration. The investigator assessed findings as abnormal.

    Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  15. Mean Change From Baseline in Heart Rate

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

    Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  16. Mean Change From Baseline in Respiratory Rate

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

    Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  17. Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

    Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  18. Mean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score

    The infusion site was assessed for pain at two time points: after placement of the infusion device but before fluid infusion and at the end of infusion. Pain was recorded using the FLACC pain scale for children less than 3 years of age. Scores on the scale ranged from 0 (no hurt) to 10 (hurt worst).

    Time frame: Before infusion (Baseline); after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  19. Number of Participants With the Indicated Type of Fluid Administered

    Data are reported for the initial fluid administered.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  20. Infusion Duration During the Initial Infusion

    Infusion duration was assessed as a measure of the time required to complete the initial infusion of 20 mL/kg.

    Time frame: first hour of infusion

  21. Change From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion

    Hydration status was assessed clinically using the Gorelick 10-item scale: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate, and capillary refill time at the fingertip. Scores ranged from 0 (less severe impairment) to 10 (more severe impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  22. Percent Change From Baseline in Body Weight

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value) \* 100.

    Time frame: Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  23. Number of Participants With the Indicated Type of Rescue Route Therapy Administered

    Participants for whom parenteral access by the randomized route of administration could not be achieved after a reasonable number of attempts and for whom the investigator had deemed the access by that route a failure were expected to receive fluid administration by other means, designated as "rescue route" for the purpose of this study. This rescue route may have included venous cut-down, central venous line, interosseous access, etc., and for those participants initially randomly assigned to IV fluid administration, SC fluid administration by hylenex-facilitated infusion.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  24. Number of Participants Classified With the Indicated Healthcare Provider Responses to the Questions Comprising the Healthcare Provider Global Satisfaction Questionnaire

    A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Was the participant successfully hydrated using the randomized route of administration?; Question 2: Overall, was the procedure of fluid infusion easy to perform?; Question 3: Were there any unacceptable side effects from the therapy?; Question 4: Would you consider using this hydration therapy for this indication in the future?

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  25. Number of Participants Classified With the Indicated Healthcare Provider Responses to the Question: How Does This Therapy Compare to Your Experience With IV (for SC Group) / SC (for IV Group) Therapy?

    A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV).

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  26. Number of Participants Classified With the Indicated Parent/Guardian Responses to the Questions Comprising the Parent / Guardian Global Satisfaction Questionnaire

    A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Do you believe the method of therapy was successful in your child's rehydration?; Question 2: Have you or your child ever previously had IV fluids (for SC Group) / SC fluids (for IV Group)?; Question 3: If the response to Question 2 was "yes," how does this compare to prior experience with IV (for SC Group) / SC (for IV Group)?; Question 4: Should your child(ren) need rehydration treatment in the future, would you opt for this procedure?; Question 5: Should you need rehydration treatment in the future, would you opt for this procedure?; Question 6: What is your global satisfaction with the study procedure?

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  27. Number of Participants With the Indicated Number of Different Anatomical Administration Sites Needed After the Start of Fluid Administration

    In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  28. Number of Participants Experiencing Reductions in Flow Rate

    In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.

    Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

  29. Number of Participants Who Received Needle Placement by People With the Indicated Level of Staff Training

    Data were collected for the level of staff training for the person who performed the needle placement.

    Time frame: average of approximately 3 minutes

  30. Number of Participants for Which the Indicated Number of Additional Personnel Was Involved in Needle Placement

    Data were collected for the number of additional personnel involved in needle placement.

    Time frame: average of approximately 3 minutes

  31. Time From the Start of Infusion to the Time of Emergency Department (ED) Discharge

    Data are reported from the start of infusion to the time of ED discharge.

    Time frame: up to approximately 26 hours

  32. Time From Randomization to the First Drop of Fluid Infusion

    Data are reported for the time from randomization to the start of fluid infusion for all randomized participants.

    Time frame: up to approximately 110 and 220 minutes for the SC and IV arms, respectively

  33. Number of Participants With the Indicated Number of Needle Stick Attempts Needed to Initiate Fluid Administration

    Data are reported for the number of needle stick attempts needed to initiate fluid administration.

    Time frame: average of approximately 3 minutes

  34. Number of Participants for Which the Indicated Type of Infusion Device Was Used

    Data are reported for the type of infusion device used.

    Time frame: average of approximately 3 minutes

  35. Number of Participants for Which the Indicated Gauge for Infusion Device Was Used

    Data are reported for the gauge of infusion device used.

    Time frame: average of approximately 3 minutes

  36. Number of Participants Discharged From the ED to Home or the Hospital

    Participants were discharged from the ED to home or the hospital to continue hydration therapy.

    Time frame: up to approximately 26 hours

  37. Number of Participants With the Indicated Reason for Rehospitalization Within 48 and 72 Hours After Discharge

    Participants were discharged from the ED to home or the hospital to continue hydration therapy.

    Time frame: from randomization up to approximately 98 hours

07

Results

Posted Nov 7, 2018

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous HylenexIntravenous Isotonic Fluid
Started7375
Initial fluids via randomized route7359
Initial fluids via subcutaneous rescue015
No fluids received01
Completed7173
Not completed22
Withdrew: Adverse event20
Withdrew: Consent withdrawn02

Outcome measures

PrimaryMean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Randomized Participants

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Randomized Participants
millilitersSubcutaneous HylenexIntravenous Isotonic Fluid
Emergency department plus hospital stay365.0 ± 324.57455.8 ± 597.43
Emergency department stay only334.3 ± 226.4299.6 ± 252.33
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.5064 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): -67.5 · 95% CI -221.2 to 86.2Treatment difference: subcutaneous minus intravenous
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.0325 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): 24.0 · 95% CI -54.6 to 102.7Treatment difference: subcutaneous minus intravenous
PrimaryMean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants
millilitersSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescued
Emergency department plus hospital stay365.0 ± 324.57579.4 ± 618.49
Emergency department stay only334.3 ± 226.4380.8 ± 223.08
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · ANOVA · p = 0.8915 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): -174.7 · 95% CI -340.3 to -9.1Treatment difference: subcutaneous minus intravenous
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · ANOVA · p = 0.5469 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): -58.6 · 95% CI -137.5 to 20.3Treatment difference: subcutaneous minus intravenous
PrimaryMean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Rescued Participants

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Rescued Participants
millilitersIntravenous Isotonic Fluid: SC Rescued
Emergency department plus hospital stay388.3 ± 281.13
Emergency department stay only315.3 ± 150.38
SecondaryMean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters
Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants
millilitersSubcutaneous HylenexIntravenous Isotonic Fluid
Emergency department plus hospital stay365.4 ± 324.21455.8 ± 597.43
Emergency department stay only334.7 ± 225.94299.6 ± 252.33
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.5035 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): -67.0 · 95% CI -220.6 to 86.7Treatment difference: subcutaneous minus intravenous
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.0314 (P-value for the test of the null hypothesis that the volume delivered via a hylenex-facilitated subcutaneous infusion was ≤85% of the volume delivered intravenously.) · Mean difference (final values): 24.6 · 95% CI -54.0 to 103.2Treatment difference: subcutaneous minus intravenous
SecondaryMean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants Achieving > 200 mL

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the Food and Drug Administration (FDA) removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

No measurements were reported for this outcome.

SecondaryMean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants Achieving > 200 mL

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

No measurements were reported for this outcome.

SecondaryMean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Rescued Participants Achieving > 200 mL

It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)

No measurements were reported for this outcome.

SecondaryMean Flow Rate, Delivered Per Unit Time, for All Randomized Participants

The mean flow rate was averaged over any 60-minute period of time.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per hour
Mean Flow Rate, Delivered Per Unit Time, for All Randomized Participants
milliliters per hourSubcutaneous HylenexIntravenous Isotonic Fluid
Emergency department plus hospital stay183.8 ± 94.61166.1 ± 142.52
Emergency department stay only186.4 ± 92.21179.6 ± 141.19
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Mean difference (final values): -30.1 · 95% CI -69.5 to 9.4Treatment difference: subcutaneous minus intravenous; Emergency department plus hospital stay
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Mean difference (final values): -40.2 · 95% CI -77.3 to -3.1Treatment difference: subcutaneous minus intravenous; Emergency department stay only
SecondaryMean Flow Rate, Delivered Per Unit Time, for All Non-rescued Participants

The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per hour
Mean Flow Rate, Delivered Per Unit Time, for All Non-rescued Participants
milliliters per hourSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescued
Emergency department plus hospital stay183.8 ± 94.61211.1 ± 127.44
Emergency department stay only186.4 ± 92.21228.3 ± 118.82
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · Mean difference (final values): -30.1 · 95% CI -69.5 to 9.4Treatment difference: subcutaneous minus intravenous; Emergency department plus hospital stay
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · Mean difference (final values): -40.2 · 95% CI -77.3 to -3.1Treatment difference: subcutaneous minus intravenous; Emergency department stay only
SecondaryMean Flow Rate, Delivered Per Unit Time, for All Rescued Participants

The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per hour
Mean Flow Rate, Delivered Per Unit Time, for All Rescued Participants
milliliters per hourIntravenous Isotonic Fluid: SC Rescued
Emergency department plus hospital stay139.1 ± 80.27
Emergency department stay only149.8 ± 79.53
SecondaryMean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Randomized Participants

The mean flow rate was averaged over any 60-minute period of time.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per kilogram per hour
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Randomized Participants
milliliters per kilogram per hourSubcutaneous HylenexIntravenous Isotonic Fluid
Emergency department plus hospital stay15.4 ± 5.6212.3 ± 9.50
Emergency department stay only15.6 ± 5.3313.3 ± 9.50
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Mean difference (final values): 2.9 · 95% CI 0.3 to 5.5Treatment difference: subcutaneous minus intravenous; Emergency department plus hospital stay
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Mean difference (final values): 2.2 · 95% CI -0.2 to 4.7Treatment difference: subcutaneous minus intravenous; Emergency department stay only
SecondaryMean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Non-rescued Participants

The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per kilogram per hour
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Non-rescued Participants
milliliters per kilogram per hourSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescued
Emergency department plus hospital stay15.4 ± 5.6215.7 ± 7.80
Emergency department stay only15.6 ± 5.3317.1 ± 7.14
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · Mean difference (final values): -0.4 · 95% CI -2.8 to 1.9Treatment difference: subcutaneous minus intravenous; Emergency department plus hospital stay
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid: Non-rescued · Mean difference (final values): -1.3 · 95% CI -3.4 to 0.8Treatment difference: subcutaneous minus intravenous; Emergency department stay only
SecondaryMean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Rescued Participants

The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · milliliters per kilogram per hour
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Rescued Participants
milliliters per kilogram per hourIntravenous Isotonic Fluid: SC Rescued
Emergency department plus hospital stay14.4 ± 6.47
Emergency department stay only15.4 ± 6.07
SecondaryNumber of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration

The maximum flow rate was averaged over any 60-minute period of time.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Number of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration6857
SecondaryNumber of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration

The number of participants administered at least 20 mL total volume was assessed.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Number of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration1827
SecondaryNumber of Participants With the Indicated Type of Adverse Events

Adverse events (AEs) are defined as any untoward medical occurrence in a participant administered a product, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events (TEAEs) are defined as those events that occurred on or after the first injection device insertion attempt.

Time frame:
up to 7 days after hospital discharge
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Type of Adverse Events
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
At least 1 AE7368
At least 1 infusion site AE7363
at least 1 AE related to infusion fluid7232
At least 1 AE related to hylenex6714
SecondaryNumber of Participants With Normal Physical Examination Findings at Baseline That Shifted to Abnormal at the End of Fluid Administration

Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion. Not Rel Dehy = Abnormal, Not Related to Dehydration; Rel Dehy = Abnormal, Related to Dehydration. The investigator assessed findings as abnormal.

Time frame:
Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants With Normal Physical Examination Findings at Baseline That Shifted to Abnormal at the End of Fluid Administration
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Head, eyes, ears: Not Rel Dehy100
Head, eyes, ears: Rel Dehy000
Neck/upper airway: Not Rel Dehy000
Neck/upper airway: Rel Dehy000
Heart: Not Rel Dehy010
Heart: Rel Dehy000
Lungs: Not Rel Dehy000
Lungs: Rel Dehy000
Abdomen: Not Rel Dehy000
Abdomen: Rel Dehy000
Skin: Not Rel Dehy012
Skin: Rel Dehy000
Musculoskeletal: Not Rel Dehy000
Musculoskeletal: Rel Dehy000
Extremities: Not Rel Dehy000
Extremities: Rel Dehy000
Neurological: Not Rel Dehy100
Neurological: Rel Dehy000
Vascular/Circulatory: Not Rel Dehy000
Vascular/Circulatory: Rel Dehy100
Lymphatic: Not Rel Dehy000
Lymphatic: Rel Dehy000
Reproductive: Not Rel Dehy000
Reproductive: Rel Dehy000
Renal/Urinary: Not Rel Dehy000
Renal/Urinary: Rel Dehy100
Endocrine/Metabolism and Nutrition: Not Rel Dehy000
Endocrine/Metabolism and Nutrition: Rel Dehy000
Other: Not Rel Dehy000
Other: Rel Dehy000
SecondaryMean Change From Baseline in Heart Rate

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

Time frame:
Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · beats per minute
Mean Change From Baseline in Heart Rate
beats per minuteSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Mean Change From Baseline in Heart Rate-6.9 ± 17.38-4.8 ± 18.64-11.3 ± 24.68
SecondaryMean Change From Baseline in Respiratory Rate

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

Time frame:
Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · breaths per minute
Mean Change From Baseline in Respiratory Rate
breaths per minuteSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Mean Change From Baseline in Respiratory Rate-4.8 ± 9.76-1.3 ± 7.96-2.6 ± 13.36
SecondaryMean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.

Time frame:
Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
millimeters of mercury (mmHg)Subcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Systolic blood pressure3.2 ± 16.151.1 ± 15.49-4.0 ± 24.17
Diastolic blood pressure-0.2 ± 12.430.7 ± 12.45-2.9 ± 23.07
SecondaryMean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score

The infusion site was assessed for pain at two time points: after placement of the infusion device but before fluid infusion and at the end of infusion. Pain was recorded using the FLACC pain scale for children less than 3 years of age. Scores on the scale ranged from 0 (no hurt) to 10 (hurt worst).

Time frame:
Before infusion (Baseline); after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · score on a scale
Mean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score
score on a scaleSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Mean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score-4.4 ± 3.45-5.2 ± 2.94-3.8 ± 2.11
SecondaryNumber of Participants With the Indicated Type of Fluid Administered

Data are reported for the initial fluid administered.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Type of Fluid Administered
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Lactated Ringers2896
Normal saline (NS)44499
D5 1/2 NS without potassium chloride (KCL)010
D5 1/2 NS with KCL000
Other100
SecondaryInfusion Duration During the Initial Infusion

Infusion duration was assessed as a measure of the time required to complete the initial infusion of 20 mL/kg.

Time frame:
first hour of infusion
Reported as:
Mean · hours
Infusion Duration During the Initial Infusion
hoursSubcutaneous HylenexIntravenous Isotonic Fluid
Infusion Duration During the Initial Infusion1.0 ± 0.130.8 ± 0.42
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Mean difference (final values): 0.2 · 95% CI 0.1 to 0.3Treatment difference = SC minus IV
SecondaryChange From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion

Hydration status was assessed clinically using the Gorelick 10-item scale: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate, and capillary refill time at the fingertip. Scores ranged from 0 (less severe impairment) to 10 (more severe impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · score on a scale
Change From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion
score on a scaleSubcutaneous HylenexIntravenous Isotonic Fluid
Change From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion-2.6 ± 1.26-2.2 ± 1.64
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.0658 · Mean difference (final values): -0.4 · 95% CI -0.9 to 0.0Treatment difference = SC minus IV.
SecondaryPercent Change From Baseline in Body Weight

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value) \* 100.

Time frame:
Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Mean · percent change
Percent Change From Baseline in Body Weight
percent changeSubcutaneous HylenexIntravenous Isotonic Fluid
Percent Change From Baseline in Body Weight2.9 ± 2.523.8 ± 15.17
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · ANOVA · p = 0.6208 · Mean difference (net): -1.0 · 95% CI -4.8 to 2.9Treatment difference = SC minus IV
SecondaryNumber of Participants With the Indicated Type of Rescue Route Therapy Administered

Participants for whom parenteral access by the randomized route of administration could not be achieved after a reasonable number of attempts and for whom the investigator had deemed the access by that route a failure were expected to receive fluid administration by other means, designated as "rescue route" for the purpose of this study. This rescue route may have included venous cut-down, central venous line, interosseous access, etc., and for those participants initially randomly assigned to IV fluid administration, SC fluid administration by hylenex-facilitated infusion.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Type of Rescue Route Therapy Administered
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
hylenex-facilitated SC015
Other type of rescue00
SecondaryNumber of Participants Classified With the Indicated Healthcare Provider Responses to the Questions Comprising the Healthcare Provider Global Satisfaction Questionnaire

A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Was the participant successfully hydrated using the randomized route of administration?; Question 2: Overall, was the procedure of fluid infusion easy to perform?; Question 3: Were there any unacceptable side effects from the therapy?; Question 4: Would you consider using this hydration therapy for this indication in the future?

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Classified With the Indicated Healthcare Provider Responses to the Questions Comprising the Healthcare Provider Global Satisfaction Questionnaire
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Question 1 — Yes6857
Question 1 — No413
Question 1 — Missing15
Question 2 — Yes6949
Question 2 — No421
Question 2 — Missing05
Question 3 — Yes34
Question 3 — No7066
Question 3 — Missing05
Question 4 — Yes7164
Question 4 — No26
Question 4 — Missing05
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0685 (Cochran-Mantel-Haenszel (CMH) test controlling for center)Question 1
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0004 (CMH test controlling for center)Question 2
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.6861 (CMH test controlling for center)Question 3
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.2323 (CMH test controlling for center)Question 4
SecondaryNumber of Participants Classified With the Indicated Healthcare Provider Responses to the Question: How Does This Therapy Compare to Your Experience With IV (for SC Group) / SC (for IV Group) Therapy?

A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV).

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Classified With the Indicated Healthcare Provider Responses to the Question: How Does This Therapy Compare to Your Experience With IV (for SC Group) / SC (for IV Group) Therapy?
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Effectiveness: Less Effective31
Effectiveness: Same Effectiveness5841
Effectiveness: More Effective110
Effectiveness: Missing10
Degree of Difficulty: Less Difficult572
Degree of Difficulty: Same Difficulty1112
Degree of Difficulty: More Difficult328
Degree of Difficulty: Missing20
Not applicable: no prior experience with alternate033
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0033 (CMH test controlling for center)Effectiveness
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = < 0.0001 (CMH test controlling for center)Degree of difficulty
SecondaryNumber of Participants Classified With the Indicated Parent/Guardian Responses to the Questions Comprising the Parent / Guardian Global Satisfaction Questionnaire

A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Do you believe the method of therapy was successful in your child's rehydration?; Question 2: Have you or your child ever previously had IV fluids (for SC Group) / SC fluids (for IV Group)?; Question 3: If the response to Question 2 was "yes," how does this compare to prior experience with IV (for SC Group) / SC (for IV Group)?; Question 4: Should your child(ren) need rehydration treatment in the future, would you opt for this procedure?; Question 5: Should you need rehydration treatment in the future, would you opt for this procedure?; Question 6: What is your global satisfaction with the study procedure?

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Classified With the Indicated Parent/Guardian Responses to the Questions Comprising the Parent / Guardian Global Satisfaction Questionnaire
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Question 1, yes7059
Question 1, no38
Question 1, missing08
Question 2, yes472
Question 2, no2663
Question 2, not done02
Question 2, missing08
Question 3, worse20
Question 3, same92
Question 3, better350
Question 3, missing10
Question 4, yes6556
Question 4, no411
Question 4, not done20
Question 4, unknown10
Question 4, missing18
Question 5, yes6855
Question 5, no412
Question 5, not done10
Question 5, missing08
Question 6, very unsatisfied38
Question 6, unsatisfied14
Question 6, satisfied2631
Question 6, very satisfied4324
Question 6, missing08
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.2012 (CMH test controlling for Center)Question 1
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = < 0.0001 (CMH test controlling for center)Question 2
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.1302 (CMH test controlling for center)Question 4
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0852 (CMH test controlling for center)Question 5
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0275 (CMH test controlling for center)Question 6
SecondaryNumber of Participants With the Indicated Number of Different Anatomical Administration Sites Needed After the Start of Fluid Administration

In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Number of Different Anatomical Administration Sites Needed After the Start of Fluid Administration
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
1 administration site725915
2 administration sites100
SecondaryNumber of Participants Experiencing Reductions in Flow Rate

In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.

Time frame:
During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Reductions in Flow Rate
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Number of Participants Experiencing Reductions in Flow Rate4339
SecondaryNumber of Participants Who Received Needle Placement by People With the Indicated Level of Staff Training

Data were collected for the level of staff training for the person who performed the needle placement.

Time frame:
average of approximately 3 minutes
Reported as:
Count of participants · Participants
Number of Participants Who Received Needle Placement by People With the Indicated Level of Staff Training
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Physician2841
Registered nurse354810
Physician assistant221
Nurse practitioner600
Licensed vocational nurse002
Other251
SecondaryNumber of Participants for Which the Indicated Number of Additional Personnel Was Involved in Needle Placement

Data were collected for the number of additional personnel involved in needle placement.

Time frame:
average of approximately 3 minutes
Reported as:
Count of participants · Participants
Number of Participants for Which the Indicated Number of Additional Personnel Was Involved in Needle Placement
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
02011
136345
214207
3332
4010
SecondaryTime From the Start of Infusion to the Time of Emergency Department (ED) Discharge

Data are reported from the start of infusion to the time of ED discharge.

Time frame:
up to approximately 26 hours
Reported as:
Mean · hours
Time From the Start of Infusion to the Time of Emergency Department (ED) Discharge
hoursSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Time From the Start of Infusion to the Time of Emergency Department (ED) Discharge4.0 ± 4.263.1 ± 1.924.7 ± 4.64
SecondaryTime From Randomization to the First Drop of Fluid Infusion

Data are reported for the time from randomization to the start of fluid infusion for all randomized participants.

Time frame:
up to approximately 110 and 220 minutes for the SC and IV arms, respectively
Reported as:
Median · minutes
Time From Randomization to the First Drop of Fluid Infusion
minutesSubcutaneous HylenexIntravenous Isotonic Fluid
Time From Randomization to the First Drop of Fluid Infusion37 (31 to 41)42.5 (37 to 52)
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Wilcoxon (Mann-Whitney) · p = 0.0247
SecondaryNumber of Participants With the Indicated Number of Needle Stick Attempts Needed to Initiate Fluid Administration

Data are reported for the number of needle stick attempts needed to initiate fluid administration.

Time frame:
average of approximately 3 minutes
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Number of Needle Stick Attempts Needed to Initiate Fluid Administration
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
16954
2413
307
>301
Statistical analysis
  • Subcutaneous Hylenex vs Intravenous Isotonic Fluid · Cochran-Mantel-Haenszel · p = 0.0007 (CMH test controlling for center)
SecondaryNumber of Participants for Which the Indicated Type of Infusion Device Was Used

Data are reported for the type of infusion device used.

Time frame:
average of approximately 3 minutes
Reported as:
Count of participants · Participants
Number of Participants for Which the Indicated Type of Infusion Device Was Used
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
Angiocatheter635715
Butterfly needle1010
Other010
SecondaryNumber of Participants for Which the Indicated Gauge for Infusion Device Was Used

Data are reported for the gauge of infusion device used.

Time frame:
average of approximately 3 minutes
Reported as:
Count of participants · Participants
Number of Participants for Which the Indicated Gauge for Infusion Device Was Used
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid: Non-rescuedIntravenous Isotonic Fluid: SC Rescued
20200
2228225
23410
24313310
25820
26010
SecondaryNumber of Participants Discharged From the ED to Home or the Hospital

Participants were discharged from the ED to home or the hospital to continue hydration therapy.

Time frame:
up to approximately 26 hours
Reported as:
Count of participants · Participants
Number of Participants Discharged From the ED to Home or the Hospital
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Home6064
Hospital1310
SecondaryNumber of Participants With the Indicated Reason for Rehospitalization Within 48 and 72 Hours After Discharge

Participants were discharged from the ED to home or the hospital to continue hydration therapy.

Time frame:
from randomization up to approximately 98 hours
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Reason for Rehospitalization Within 48 and 72 Hours After Discharge
ParticipantsSubcutaneous HylenexIntravenous Isotonic Fluid
Retreatment for dehydration22
Other78

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous Hylenex1/73 (1.4%)3/73 (4.1%)73/73 (100%)
Intravenous Isotonic Fluid0/75 (0%)4/75 (5.3%)62/75 (82.7%)
Most frequent serious events
Most frequent serious events
EventSubcutaneous HylenexIntravenous Isotonic Fluid
Viral gastroenteritisInfections and infestations1/730/75
PneumoniaInfections and infestations1/730/75
Cardio-respiratory ArrestCardiac disorders1/730/75
GastroenteritisInfections and infestations1/730/75
PyrexiaGeneral disorders0/731/75
Ongoing dehydrationMetabolism and nutrition disorders0/731/75
Rotavirus infectionInfections and infestations0/731/75
Kawasaki diseaseVascular disorders0/731/75
Most frequent other events
Most frequent other events
EventSubcutaneous HylenexIntravenous Isotonic Fluid
Infusion site swellingGeneral disorders59/7316/75
Infusion site painGeneral disorders57/7359/75
Infusion site erythemaGeneral disorders54/7319/75
Infusion site oedemaGeneral disorders5/731/75
Infusion site haematomaGeneral disorders0/733/75
PyrexiaGeneral disorders2/732/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)Subcutaneous HylenexIntravenous Isotonic FluidTotal
Mean2.1 ± 1.722.4 ± 2.072.3 ± 1.91
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous HylenexIntravenous Isotonic FluidTotal
Female393675
Male343973
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Subcutaneous HylenexIntravenous Isotonic FluidTotal
American Indian or Alaska Native000
Asian000
Black or African American252247
White394079
Native Hawaiian or Pacific Islander011
Unknown91221
08

Study locations

25 sites
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • Tampa General Hospital Children's Medical Center
    Tampa, Florida 33606, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Children's Healthcare of Atlanta - Scottish Rite
    Atlanta, Georgia 30342, United States
  • North Georgia Clinical Research
    Dalton, Georgia 30721, United States
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • Memorial Hospital
    South Bend, Indiana 46601, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • William Beaumont Hospital
    Troy, Michigan 48085, United States
  • The Children's Mercy Hospital & Clinics
    Kansas City, Missouri 64108, United States
  • UMDNJ/Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • St. Joseph's Children's Hospital
    Paterson, New Jersey 07503, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • Children's Hospital at Montefiore
    Bronx, New York 10956, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • Staten Island University Hospital Emergency Department
    Staten Island, New York 10305, United States
  • Rainbow Children's and Babies Hospital
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Dell Children's Medical Center
    Austin, Texas 78723, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Spandorfer PR, Mace SE, Okada PJ, Simon HK, Allen CH, Spiro DM, Friend K, Harb G, Lebel F; Increased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration II (INFUSE-Peds II) Study Group. A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department. Clin Ther. 2012 Nov;34(11):2232-45. doi: 10.1016/j.clinthera.2012.09.011. Epub 2012 Oct 11. PubMed 23062548 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 9 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2008
First posted
Oct 16, 2008
Start
Oct 2008
Primary completionActual
Nov 2009
CompletionActual
Dec 2009
Results first posted
Nov 7, 2018
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00773175
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Oct 2008
Primary completion
Nov 2009
Completion
Dec 2009
Results posted
Nov 7, 2018
Last update
Nov 7, 2018

Study contacts

Coburn H Allen, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion